DNA

ANALYST NOTE: DNA (Ginkgo Bioworks Holdings, Inc.) Date: 2026-06-13 Current Price: $9.17

1. Structural Readiness

Conservative Entry: Not yet actionable. A conservative entry requires a confirmed breakout above the coil resistance. Aggressive/Pre-Breakout Entry: Not applicable for a "forming" coil in a conservative framework; the setup is currently a watch-list candidate pending a breakout confirmation. Breakout Level: Not yet established; requires price to close above the coil's resistance zone. Current Price: $9.17. Extension: Not applicable (price is within the coil structure, not extended above it). ATR Context: Current ATR is 7.9% (Very High). This indicates elevated volatility, which increases the risk of whipsaws during the formation phase but suggests significant potential for a large move once the breakout occurs.

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led. There is no named secular thesis attached to this name as of 2026-06-13. The investment case is not driven by a broad macro theme (e.g., "AI in Biology" or "Global Biosecurity Boom") but is strictly a function of the structural setup quality and the specific operational fundamentals disclosed by management. The conviction must be derived entirely from the execution of the restructuring and the stability of the cash burn, rather than a secular tailwind.

3. Business Overview

Company Description: Ginkgo Bioworks Holdings, Inc. operates as a platform for the engineering of cells, providing tools and biological R&D services to government and commercial customers. Business Model & Segments:

• Cell Engineering: Provides tools and services across industries including chemical manufacturing, agriculture, food production, consumer goods, and pharmaceuticals. The company shifts its downstream value capture toward milestone payments and commercial royalties rather than equity stakes, a change announced in Q2 2024 and active in 2026.
• Biosecurity: Focuses on scalable infrastructure through offerings named "Canopy" and "Horizon," serving primarily government customers seeking to protect against biological threats.
• Automation (RAC): Sells RAC (Robotics and Automation) systems. Fees for these solutions are earned over 6–12 months covering design, build, and deployment.

Key Operational Evidence (as of May 2026):

• Capacity Expansion: Management stated on May 7, 2026, that "103 racks will be coming online just in about a week, all in one big setup here in Boston."
• Customer Base: The company is "working with 10 of the top biopharma companies in the world" in the first year of its new operational model.
• Autonomous Labs: Management is building autonomous labs for early adopters, positioning them as an alternative to traditional lab benches.
• Contractual Obligations: In April 2026, the company restricted $47.0 million of cash to secure a surety bond for a U.S. Government National Laboratory contract regarding RAC automation equipment.

4. Archetype and Conviction Analysis

Archetype: Structurally Broken. The company is in a phase of active restructuring and stabilization. The "broken" nature is evidenced by the need to reduce cash burn and restructure operations, yet the company is demonstrating signs of stabilization through cost controls and capacity expansion.

Fundamental Context:

• Cost Discipline: Management reaffirmed a cash burn guidance of $125 million to $150 million for 2026. R&D expenses decreased 38% year-over-year in Q1 2026 (from $49 million to $30 million).
• Operational Stability: Management expects R&D expenses to "remain consistent or decline in 2026," reflecting the stabilization of operational overhead.
• Valuation/Financials: The financial spine indicates a forward consensus EPS of -4.33 for FY1 and -3.77 for FY2. The company remains unprofitable, but the trajectory suggests a narrowing of losses.

Conviction Stack:

• Thesis Strength: Low (Tactical only).
• Evidence Quality: High. Multiple primary sources (earnings transcripts, SEC filings) from May 2026 confirm specific operational metrics, cost reductions, and capacity additions.
• Structural Quality: Moderate. The "Structurally Broken" archetype implies a difficult path to profitability, but the specific evidence of cost cuts and new capacity adds credibility to the turnaround narrative.
• Setup Readiness: Partial. The coil is "forming," meaning the structure is present but the catalyst (breakout) has not occurred.
• Rerating Potential: Dependent on the successful execution of the cost-cutting plan and the monetization of the new RAC and autonomous lab capacity.

ATR Analysis: The current ATR of 7.9% falls into the Very High bucket (6–8%). In the StoryStocks canon, this is elevated volatility. While it offers the potential for a large move, it also carries a higher historical rate of "severe losers" if the setup fails. This volatility suggests that position sizing must be conservative until the breakout is confirmed.

5. Invalidating and Strengthening Factors

Invalidation Triggers:

• Fundamental Deterioration: If management raises the 2026 cash burn guidance above $150 million or fails to maintain the R&D expense reduction trajectory, the "stabilization" thesis would be broken.
• Liquidity Constraints: Any new restrictions on cash beyond the $47 million surety bond that threaten the ability to fund the $125–$150 million burn rate.

Strengthening Factors:

• Breakout Confirmation: A close above the coil resistance with volume would confirm the "Structurally Broken" recovery.
• Revenue Acceleration: Evidence of the "103 racks" and "autonomous labs" translating into faster revenue recognition or higher contract values.
• Further Cost Reduction: Confirmation that R&D expenses continue to decline or remain flat while revenue grows.

Evidence Gaps:

• Revenue Growth Rate: While cost cuts are well-documented, specific revenue growth figures for Q1 2026 or full-year 2026 guidance are not explicitly detailed in the provided evidence, making it difficult to assess the top-line impact of the new capacity.
• Profitability Timeline: The financial spine shows negative EPS for FY1 and FY2. There is no specific management guidance on *when* the company expects to reach breakeven, only that burn is being managed.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: R&D expenses decreased 38% YoY to $30 million in Q1 2026; 103 new automation racks coming online in Boston; cash burn guidance reaffirmed at $125M-$150M for 2026. Key risks: Current ATR of 7.9% indicates very high volatility and elevated risk of whipsaw; company remains unprofitable with negative forward EPS; reliance on government contracts and large pharma partnerships for revenue stability. Sizing hint: Position size should be reduced relative to standard setups due to the "very high" ATR and the "forming" (unconfirmed) nature of the coil. Expected path: Management expects R&D expenses to remain consistent or decline as operational overhead stabilizes; the new capacity (103 racks) should drive utilization and revenue recognition over the next 6-12 months. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).